OptiNose, Inc. (OPTN) Analysts See $-0.68 EPS

November 10, 2018 - By Hannah Black

Analysts expect OptiNose, Inc. (NASDAQ:OPTN) to report $-0.68 EPS on November, 26.They anticipate $3.55 EPS change or 83.92 % from last quarter’s $-4.23 EPS. After having $-0.64 EPS previously, OptiNose, Inc.’s analysts see 6.25 % EPS growth. The stock decreased 1.81% or $0.2 during the last trading session, reaching $10.87. About 121,683 shares traded. OptiNose, Inc. (NASDAQ:OPTN) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company has market cap of $448.14 million. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It currently has negative earnings. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

More recent OptiNose, Inc. (NASDAQ:OPTN) news were published by: Globenewswire.com which released: “Optinose to Report Third Quarter 2018 Financial Results and Corporate Updates on November 13, 2018” on October 31, 2018. Also Globenewswire.com published the news titled: “Detailed Research: Economic Perspectives on Caseys General Stores, Evolus, OptiNose, Xunlei, Molina Healthcare …” on October 22, 2018. Seekingalpha.com‘s news article titled: “CVS Health Is Still A Buy – Cramer’s Lightning Round (10/11/18)” with publication date: October 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.